ERBB2 and breast carcinoma: In a phase II RCT, compared with lapatinib plus capecitabine, pyrotinib plus capecitabine significantly improved ORR (78.5 vs. 57.1%) and prolonged progression-free survival (PFS) (18.1 vs. 7.0 months) in patients with HER2-positive advanced breast cancer.